Brief: Adagene Announces Publication At Asco Of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile Of Anti-Ctla-4 Safebody® Adg126, With Repeat Dosing Across Dose Levels
27/05/2022 24:45
May 26 (Reuters) - Adagene Inc 978y.F :
* ADAGENE ANNOUNCES PUBLICATION AT ASCO OF INTERIM
MONOTHERAPY
DOSE ESCALATION DATA SHOWING COMPELLING SAFETY PROFILE OF
ANTI-CTLA-4 SAFEBODY® ADG126, WITH REPEAT DOSING ACROSS DOSE
LEVELS
* ADAGENE INC - ADDITIONAL DATA FROM ONGOING ADG126 CLINICAL
PROGRAM TO BE PRESENTED IN SECOND HALF OF 2022
Source text for Eikon: ID:nGNX6QVNFj
Further company coverage: 978y.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adagene
See all newsBrief: Adagene To Begin Phase 1 Study Of ADG138 For Advanced Solid Tumors In Q4 2026
Brief: Adagene Announces That Third Arc Bio Has Selected First Lead Candidate Under Amended Strategic Collaboration For Development Of Masked Cd3 T Cell Engagers Utilizing Safebody® Technology
Brief: Adagene Inc Announces Offering Of American Depositary Shares
Brief: Adagene Announces FDA Fast Track Designation For Muzastotug (Adg126)
Brief: Adagene Expands SAFEBody Deal With Exelixis To Develop Third Novel Masked Antibody-Drug Conjugate